CJC-1295 / Ipamorelin: Dual GH-Axis Stimulation in Research Models

CJC-1295 (Without DAC): A Stabilised GHRH Analogue

CJC-1295 is a modified analogue of growth hormone-releasing hormone 1–29 [GRF(1-29)NH2], the biologically active N-terminal fragment of endogenous GHRH. The native GRF(1-29) sequence is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) at the Ala⁸-Gly⁹ bond, giving it a plasma half-life of approximately 7 minutes in vivo — too short for practical use as a research tool in chronic stimulation protocols.

CJC-1295 incorporates four amino acid substitutions — at positions 2, 8, 15, and 27 of the GRF(1-29) sequence — specifically chosen to resist DPP-IV cleavage and metabolic degradation while preserving receptor-binding affinity at the pituitary GHRH receptor (GHRHR). These substitutions extend the half-life of the compound substantially, though the exact duration depends on the presence or absence of a Drug Affinity Complex (DAC) conjugate.

The formulation referred to as "CJC-1295 without DAC" lacks the C18-fatty acid DAC conjugate that, when present, binds covalently to serum albumin and extends half-life to approximately 6–8 days. Without DAC, the compound has a half-life of approximately 30 minutes — producing a more pulsatile, physiological pattern of GH release rather than the sustained, non-pulsatile elevation associated with the DAC-conjugated form. This pulsatility is considered important in GH axis research because endogenous GH is secreted in discrete pulses, and sustained non-pulsatile elevation has different downstream effects on IGF-1 and tissue responses.

Mechanistically, CJC-1295 without DAC binds to the pituitary GHRHR, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). This signalling cascade promotes both GH synthesis in somatotroph cells and GH secretory vesicle exocytosis, producing a dose-dependent elevation of circulating GH.

Ionescu and Frohman (2006) demonstrated in a human clinical study that CJC-1295 (using the DAC form) produced dose-dependent, sustained elevation of plasma GH and IGF-1 levels in healthy adults. The without-DAC formulation studied in research protocols produces shorter-duration GH pulses of similar amplitude, more closely approximating natural secretory patterns.

Ipamorelin: A Selective Growth Hormone Secretagogue

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2Nal-D-Phe-Lys-NH2, developed from the growth hormone-releasing peptide (GHRP) lineage that includes GHRP-2 and GHRP-6. Its critical distinguishing feature is receptor selectivity: Ipamorelin is a highly selective agonist at the growth hormone secretagogue receptor subtype 1a (GHS-R1a) with minimal activity at other receptors in the GHRP class that produce off-target effects.

Specifically, GHRP-2 and GHRP-6 — earlier compounds in this class — stimulate GH release effectively but also produce significant elevations in cortisol and prolactin via activation of non-GHS-R1a pathways. These off-target hormonal effects complicate the interpretation of research data and create confounds in experimental models. Ipamorelin was developed to eliminate these confounds. Raun K and colleagues (1998) characterised Ipamorelin's selectivity profile in detail, demonstrating GH stimulation comparable to GHRP-6 with negligible cortisol or prolactin elevation — a profile that made it a preferred research tool for GH axis studies.

Ipamorelin's mechanism of action involves agonism at GHS-R1a, which is the endogenous receptor for ghrelin — the stomach-derived peptide that stimulates GH release and appetite. GHS-R1a agonism activates the phospholipase C / inositol triphosphate (IP3) intracellular signalling pathway, distinct from the adenylyl cyclase / cAMP pathway activated by GHRHR agonists such as CJC-1295. This mechanistic distinctiveness is what enables synergistic rather than merely additive GH release when both compounds are used together in research protocols.

Synergy: The Two-Receptor Hypothesis

The theoretical basis for the synergistic GH-releasing effect of GHRH analogues combined with GHRPs was formalised by Veldhuis JD and colleagues (1997) in the "two-receptor hypothesis" for GH pulsatility. This model proposes that maximal physiological GH pulse amplitude requires concurrent activation of both the GHRHR and GHS-R1a pathways, with the combined signal exceeding what either pathway produces in isolation.

The mechanistic components of this synergy are as follows:

• CJC-1295 (GHRHR agonism): activates the cAMP/PKA signalling cascade in pituitary somatotroph cells, priming the cellular machinery for GH synthesis and vesicle release.
• Ipamorelin (GHS-R1a agonism): activates the phospholipase C / IP3 pathway, independently driving GH vesicle exocytosis. Additionally, GHS-R1a agonism suppresses somatostatin release from the hypothalamus. Somatostatin (growth hormone-inhibiting hormone) is the primary brake on GH secretion; its suppression removes a constraint on the GH pulse amplitude that GHRH stimulation alone cannot overcome.
• Combined effect: with somatostatin suppressed and both the cAMP and IP3 intracellular pathways concurrently activated, the resulting GH pulse amplitude is substantially greater than the sum of either agent's individual contribution — the hallmark of true pharmacological synergy rather than simple additivity.

This synergy has practical implications for research protocol design, as the combined administration allows GH axis stimulation at lower individual doses of each component compared to what would be required to achieve equivalent stimulation with either agent alone.

Dosing in Preclinical and Clinical Research

In rodent research models, CJC-1295 is typically used at doses of 100–300 µg/kg, and Ipamorelin at 100–300 µg/kg, administered subcutaneously or intraperitoneally. Human trial doses for CJC-1295 in the Ionescu and Frohman (2006) study ranged from 30 to 120 µg/kg. Administration timing in GH axis research is typically designed to coincide with or augment natural GH pulse windows (e.g. early sleep phase in rodent models).

Co-Lyophilised Blend Considerations

Novahelix supplies CJC-1295 and Ipamorelin as a co-lyophilised blend in a single vial. Co-lyophilisation preserves both peptides in their individual chemical forms within the same matrix, maintaining the individual purity of each component. The blend should be reconstituted in bacteriostatic water before use, following standard peptide reconstitution protocols. Researchers should verify that the concentration of each component in the reconstituted solution matches their protocol requirements, as the fixed ratio in the co-lyophilised blend may require concentration adjustment for specific dose-finding experiments.

IGF-1 Axis as a Research Endpoint

Growth hormone stimulation produces downstream elevation of insulin-like growth factor 1 (IGF-1), primarily synthesised in the liver in response to GH receptor activation. Many GH axis research studies measure both acute plasma GH (to confirm immediate secretory response) and IGF-1 at 24–72 hours post-dose (to assess the downstream hepatic response). The dual-measurement approach provides a more complete picture of GH axis engagement than GH alone, and is standard practice in preclinical GH secretagogue research.